文献速递其他结缔组织病系统性红斑狼疮类风湿关节炎

耐受性细胞疗法在自身免疫病中的前景

Tolerising cellular therapies: what is their promise for autoimmune disease?
PubMed 文献 · Ann Rheum Dis · 2018-11-02

本文综述了自身免疫病中耐受性细胞疗法的潜力,重点讨论间充质基质细胞、耐受性树突状细胞和调节性T细胞三类疗法。文章指出,理想策略是在组织损伤累积前重建自身耐受,并综合临床前与人体数据探讨其开发路径与未来角色。

要点

  • 核心思路是用体外生成的耐受性免疫细胞重建自身耐受。
  • 重点评估间充质基质细胞、耐受性树突状细胞和调节性T细胞三类疗法。
  • 定制化与通用型产品的取舍及特定临床场景适用性各有利弊。

核心结论

  • 在组织损伤累积前重建自身耐受是自身免疫病理想治疗策略,耐受性细胞疗法具备可行治疗前景。

研究设计与样本

  • 综述,先简要概述临床前数据,再全面讨论人体数据,并围绕开发路径与未来角色展开讨论。

主要发现

  • 多种人类自身免疫病中存在调节性T细胞等关键免疫细胞的缺陷或调控异常。
  • 近年来已开发出间充质基质细胞、耐受性树突状细胞和调节性T细胞等潜在耐受性细胞疗法。
  • 细胞制造技术的同步进步有望在证实安全性与有效性后实现可扩展、可负担的干预。

临床怎么用

  • 综述提示耐受性细胞疗法可作为重建自身耐受的候选策略,具体应用需结合各疗法利弊与临床场景评估。

局限性

  • 本文为综述,未报告具体研究设计、样本量或疗效数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current management of autoimmunity involves the administration of immunosuppressive drugs coupled to symptomatic and functional interventions such as anti-inflammatory therapies and hormone replacement. Given the chronic nature of autoimmunity, however, the ideal therapeutic strategy would be to reinduce self-tolerance before significant tissue damage has accrued. Defects in, or defective regulation of, key immune cells such as regulatory T cells have been documented in several types of human autoimmunity. Consequently, it has been suggested that the administration of ex vivo generated, tolerogenic immune cell populations could provide a tractable therapeutic strategy. Several potentially tolerogenic cellular therapies have been developed in recent years; concurrent advances in cell manufacturing technologies promise scalable, affordable interventions if safety and efficacy can be demonstrated. These therapies include mesenchymal stromal cells, tolerogenic dendritic cells and regulatory T cells. Each has advantages and disadvantages, particularly in terms of the requirement for a bespoke versus an 'off-the-shelf' treatment but also their suitability in particular clinical scenarios. In this review, we examine the current evidence for these three types of cellular therapy, in the context of a broader discussion around potential development pathway(s) and their likely future role. A brief overview of preclinical data is followed by a comprehensive discussion of human data.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Mosanya CH, Isaacs JD. Tolerising cellular therapies: what is their promise for autoimmune disease? Ann Rheum Dis. 2018. PMID: 30389690. doi:10.1136/annrheumdis-2018-214024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。